Hepatitis B infection in people living with HIV who initiate antiretroviral therapy in Zimbabwe.

ABSTRACT:

Setting

There is little information about the diagnosis and treatment of hepatitis B virus (HBV) infection in people living with HIV (PLHIV) in Zimbabwe despite recommendations that tenofovir (TDF) + lamivudine (3TC) is the most effective nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) backbone of antiretroviral therapy (ART) in those with dual infection.

Objective

To determine 1) numbers screened for hepatitis B surface antigen (HBsAg); 2) numbers diagnosed HBsAg-positive along with baseline characteristics; and 3) NRTI backbones used among PLHIV initiating first-line ART at Mpilo Opportunistic Infections Clinic, Bulawayo, Zimbabwe, between October 2017 and April 2019.

Design

This was a cross-sectional study using routinely collected data.

Results

SUBMITTER: Goverwa-Sibanda TP 

PROVIDER: S-EPMC7577008 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature